Frank Armstrong has held Chief Executive roles with five biotechnology companies (both public and private) including Fulcrum Pharma PLC (AIM). He led Medical Science and Innovation at Merck Serono and was previously Executive Vice President of Product Development at Bayer and Senior Vice President of Medical Research and Communications at Zeneca. Dr Armstrong is currently the Chairman of Summit Therapeutics (AIM and NASDAQ) and Caldan Therapeutics and a Non-Executive Director of Juniper Therapeutics (NASDAQ) and Mereo Pharma (AIM) He is a Strategic Advisory Board Member at Healthcare Royalty Partners and Epidarex Capital. Dr Armstrong is a Member of the Court of the University of Edinburgh. Dr Armstrong is a physician and a Fellow of the Royal College of Physicians (Edinburgh). He was appointed as a Non-Executive Director of the Company in September 2015.